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Abstract: For the first time, we discovered a small proportion of aqueous fraction from Saw Palmetto
apart from the fatty acid-rich fraction exhibited pharmacological activity. Therefore, this study aims
to explore the anti-tumor potential of red pigmented aqueous fraction of Saw Palmetto, NYG on
human hepatocellular carcinoma and its possible targets. Subcutaneous xenograft and orthotopic
implantation models of HCC were used to evaluate the tumor inhibitory effect of NYG. Human
hepatocellular carcinoma (HCC) cell lines and human umbilical vein endothelial cells (HUVEC)
were used as in vitro model. The mRNA expression was conducted by qPCR. Protein expression
was monitored by immunoblotting and immunohistochemistry. Cell migration and blood vessel
formation were determined by chamber assay and tube formation assay, respectively. Significant
tumor inhibition of NYG in dose-dependent manner was observed on subcutaneous xenograft and
orthotopic HCC model. NYG has no direct action on cell viability or VEGF secretion of HCC cells.
However, NYG reduced in vitro migration and vessel formation activities of HUVEC cells, as well as
in vivo intratumoral neovascularization. NYG attenuated extracellular signal-regulated kinases (ERK)
activation in endothelial cells, which may be associated with the suppression of migration and tube
formation of HUVEC. NYG suppressed tumor expansion of HCC via inhibiting neovascularization,
and may be potential adjuvant treatment for HCC.
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1. Introduction
Liver cancer is one of the most prevalent human malignancies all over the world. As the sixth most
common cancer, there are 782,000 new cases of liver cancer diagnosed annually and the death rate is
increasing annually [1]. High mortality rate due to liver cancer was reported in Asia and Africa regions,
especially in those less developed countries [2]. Hepatocellular carcinoma (HCC) is the major form,
accounting for 85% of liver cancer cases. Treatments for HCC are limited, and operation including liver
transplantation and surgical resection is the best prognosis across different treatments [3]. However,
only 15% of HCC patients diagnosed are suitable for surgical methods, and non-surgical treatment is
still under great demand. Unfortunately, as most HCC are highly radio- and chemo-resistant, desirable
therapeutic outcome is hardly achieved in clinical cases with general cancer treatment protocols [4].
Therefore, therapeutic agents that specifically and effectively target on HCC are always in need. Tumor
neovascularization is the process in which endothelial cells of intra-tumoral blood vessel proliferates
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and migrates to form new vasculatures, in order to supply oxygen and nutrients for the rapid growth
of tumor cells [5]. Agents in blocking tumor neovascularization in HCC are available, and sorafenib
was recently approved by FDA in targeting this process for HCC treatment [6]. Although sorafenib
may extend the life span of HCC patients, the treatment is associated with various adverse effects
that cannot be neglected, and the high cost of sorafenib renders financial burden to the patients [7].
Therefore, searching for an alternative medicine targeting on tumor neovascularization for treatment
of HCC is still of interest.
Saw Palmetto is the fruit extract of Serenoa repens (Bartram) J.K.Small, an edible plant originated
from Southeastern United States. Approximately 90% of its containing fatty acids are currently
manufactured as a nutrient supplement for its therapeutic efficacy on benign prostatic hyperplasia
(BPH) [8]. Apart from its well-known effect in BPH patient, the pharmacological effects of saw
palmetto such as immune-modulatory effect [9] and inhibitory effect in lipid droplet and adipocyte
accumulation are also extensively explored [10]. Previous studies showed the in vitro anti-cancer effect
of lipidosterolic fraction of Saw Palmetto through inducing cell apoptosis in cancer cell lines [11].
In vivo study using transgenic prostate adenocarcinoma murine model also postulated that the
administration of lipidosterolic extract (300 mg/kg/day) may prevent tumor occurrence [12]. However,
epidemiology [13] and randomized trials [14] demonstrated that there is no association of prostate
cancer risk between the intervention and placebo group. Although the result discrepancy between the
studies may not conclude the effect of Saw Palmetto lipidosterolic extract in prostate cancer prevention,
we could not preclude the potential anti-tumor effect of Saw Palmetto in other tumor models. Fatty
acids are key components of Saw Palmetto and may majorly contribute to the abovementioned
pharmacological actions; nonetheless, a small proportion of natural pigment compounds have also
been isolated from the commercial Saw Palmetto Extract [15]. To date, no previous study has reported
any bioactivity of these pigmented fractions from Saw Palmetto.
In this study, we reported for the first time the anti-tumor activity of the Saw Palmetto red
pigmented aqueous fraction named NYG (patent number: WO 2014174703 A1). We employed the
murine subcutaneous and orthotopic HCC models to investigate any tumor regression after NYG
treatment, and probed out its possible target with multiple cell models. We found that NYG exhibited
potent inhibitory effect on xenograft and orthotopic growth of HCC as well as reduced the in vivo
neovascularization. However, we did not observed any effect of NYG on the in vitro viability and
proliferation of HCC cells; it also did not reduce the secretion of neovascularization-favoring factor,
vascular endothelial growth factor (VEGF), from tumor cells. Instead, NYG reduced the migration and
blood vessel formation of endothelial cells throughout tumor stroma. Suppression of VEGF-induced
ERK activation may be involved in the pharmacological action of NYG on endothelial cells. Our
results shed light on the potential of Saw Palmetto aqueous fraction as adjuvant treatment of HCC via
targeting tumor neovascularization.
2. Results
2.1. NYG Suppressed Xenograft Growth of Hepatocellular Carcinoma (HCC) in Vivo
The lipidosterolic fraction of Saw Palmetto is frequently studied and actively used as health
supplement for prevention of BPH and hair loss. Its aqueous fraction is rarely investigated, however,
a previous study showed that the acidic water extract of Saw Palmetto exhibited anti-oxidant and
COX-2 inhibitory effect [16]. This observation also further supported another study on the inhibitory
activity of Saw Palmetto berry extract on COX-2, which is associated with its prostate cancer cell
growth suppression [17]. In accordance with the previous study, we hypothesized that the aqueous
fraction of Saw Palmetto may exhibit tumor inhibitory effect. The water-soluble fraction, namely
NYG, was prepared following stringent manufacturing practice by Heimat Co., Ltd. (Tokyo, Japan).
Our preliminary compound characterization using thin layer chromatography has suggested that
the containing compounds of NYG are mainly composed of proanthocyanidins and oil elements.
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Further study in compound characterization using other means is essentially needed to confirm the
ingredients contained and serve as quality control of NYG. As NYG is a novel fraction isolated from
Saw Palmetto, we first examined its toxicity by dose escalation method. Mice were treated with NYG at
doses of 0.1, 1, 10 and 100 mg/kg via intraperitoneal injection on five consecutive days. One day after
injection, four out of five mice at treatment group of 100 mg/kg died, while mice in the other groups
exhibited normal behavior. After four-days of intervention, the mice in 100 mg/kg NYG treatment
group died (Figure 1A). The LD50 of single treatment was calculated as approximately 66.3 mg/kg.
NYG administration below LD50 is considered safe.
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Figure 1. NYG suppressed xenograft growth of HCC in vivo. (A) Mice were treated with 0.1, 1, 10 and
100 mg/kg of NYG (i.p.) on five consecutive days (n = 5); (B,C) Subcutaneous xenograft mice were
treated with NYG, either 5 mg/kg or 10 mg/kg, via i.p. injection. The body weight was monitored and
measured as average of replicates (n = 5) with standard deviation; (D) The tumors were excised and
measured as average ˘ SD (mm3). The tumor size of NYG (10 mg/kg) treatment group is smaller than
the saline-given mice group; The subcutaneous tumor growth is indicated by circle; (E) The tumor size
was monitored and measured every week after subcutaneous injection of tumor cells; (F) Histological
sections of excised hepatocellular carcinoma (HCC) tumor staining with cluster of differentiation 31
(CD31) antibody in control and NYG-treated mice (10 mg/kg). The vascular dens ty of ch section
was measured as the mean number of microvessel in five histological areas (100ˆ magnification); NYG
intervention significantly reduced CD31-stained microvessel density in xenograft mice. *** p < 0.001.
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Next, we examined the in vivo anti-tumor effect of NYG on xenograft growth of MHCC97L
cell in nude mice. NYG treatment (5 mg/kg and 10 mg/kg every two days) was administrated
intraperitoneally after one week of tumor inoculation. PBS and beta-cyclodextrin (B-CD) was given
to negative control groups of mice while mice receiving doxorubicin (2.5 mg/kg) served as positive
control. We observed that treatment of NYG exhibited least toxicity to the mice, as evidenced by
maintenance of body weight during the whole treatment (Figure 1B). As postulated in Figure 1C, the
mice group intervened with NYG (10 mg/kg) exhibited slower growth rate of HCC cells compared to
vehicle receiving group. Both doses of NYG administration reduced tumor size by the end of four-week
treatment; while NYG in 10 mg/kg demonstrated much potent tumor inhibitory effect suggested the
dose-dependent efficacy of NYG (Figure 1D,E). Treatment of B-CD, the pharmaceutical excipient of
NYG showed minimal effect on tumor growth and body weight of mice (Figure 1B,E), which reflected
that the anti-tumor activity on human HCC is solely contributed by NYG itself. Immunostaining
of CD31 on xenograft HCC tumor showed significant reduced micro-vessel formation after NYG
intervention (Figure 1F). Overall, these results postulate that NYG inhibited HCC xenograft growth
and the effect is mainly contributed by reduced angiogenesis in tumor environment.
2.2. NYG Inhibited Orthotopic Implanted HCC Growth in Vivo
Xenograft model is often used as the first line model for investigating the anti-cancer efficacy
of new therapeutic agents, however, this preclinical model has its limitation in reflecting the liver
tumor microenvironment and renders poor prognostic outcome of drug efficacy [18]. Therefore,
we established the orthotopic HCC implantation model in which the MHCC97L cells tagged with
luciferase are implanted onto the right lobe of mice liver. The orthotopic HCC tumor growth will
be monitored by live-animal imaging throughout the intervention period. After one-week of model
establishment, the mice with observable luciferase intensity will be chosen and further randomized
into two groups: Negative control group receiving PBS, and NYG (10 mg/kg) intervention group.
As observed from the luciferase signal intensity plot, the orthotopic HCC tumor growth rate was
decelerated in NYG intervened mice group after Week 2 of treatment (Figure 2A), while the tumor
growth of vehicle-receiving mice group increased exponentially within five weeks. By the end of
experiment, we observed significant reduction in liver tumor size of NYG-intervened group, which
accounted for approximately 60% suppression of HCC tumor growth in NYG-treated mice as compared
to control mice (Figure 2B). Similar to subcutaneously grown tumor, NYG intervention also significantly
reduced CD31-positive cell populations in orthotopically-grown liver tumor, suggested the tumor
inhibitory effect of NYG on orthotopic implanted HCC growth may be partly contributed by reduced
neovascularization by NYG (Figure 2C).
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Figure 2. NYG inhibited orthotopic growth of HCC in vivo. (A) The orthotopic growth of HCC was
monitored by imaging of luciferin signal every week after model establishment. The orthotopic HCC
growth rate is slower in NYG treatment group as compared to saline-given group of mice; (B) The
liver were excised after five weeks of NYG treatment. The representative photograph showed reduced
orthotopic tumor growth in NYG-treated mice group as compared to saline-treated group. After NYG
treatment, the significant reduced tumor volume is observed; The orthotopic grown tumor nodules
are indicated by circle; (C) Histological sections of excised orthotopic HCC tumor staining with CD31
antibody in control and NYG-treated mice (10 mg/kg). The vascular density of each section was
measured as the mean number of microvessels in five histological areas (100ˆ magnification). NYG
intervention significantly reduced CD31-stained microvessel density in orthotopic HCC implanted
mice. ** p < 0.01.
2.3. NYG Exerted Minimal Effect on in Vitro Cultured HCC Cells
To elucidate the effect of NYG, we further investigated whether the fraction suppresses HCC cell
proliferation. The MTT assay was performed to examine the cytotoxic doses of NYG on individual
HCC cells. Surprisingly, NYG up to 500 µg/mL exhibited no potent cytotoxicity to HepG2 and
MHCC97L, the two human hepatocellular carcinoma cell lines, even if the incubation time is extended
to 72 h (Figure 3A,B). As expected from the minimal toxicity incurred by NYG on HCC cells, NYG
also exerted no cytotoxicity on normal hepatic cell line L-02, up to concentration of 500 µg/mL
(Figure 3C). Prompted by the observation of reduced CD31-stained in vivo vascular cell density, we
further examined the expression of VEGF, the angiogenic-favoring factor in NYG-treated HCC cells.
The MHCC97L c lls w re supplemented with 250 and 500 µg/mL of NYG; the cells and culture
supernatant were harvested after 48 h of incubation. The qua tita ive PCR analysis showed that NYG
intervention has least effect on mRNA expression of VEGF, in both normoxia and hypoxic condition
(Figure 3D). To validate, th secretion of VEGF protein by MHCC97L cells was d termined by ELISA
assay, nd we did not observed any inhibition on VEGF s cretion by NYG (Figure 3E). These results
indicate that the tumor inhibitory effect of NYG was independent to its action on HCC cells.
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Figure 3. NYG exerted minimal effect on in vitro cultured HCC cells. (A) HepG2 and (B) MHCC97L
cell lines were treated with NYG ranging from 0 to 500 µg/mL at 24, 48 and 72 h of incubation.
Beta-cyclodextrin (B-CD), suramin and sorafenib served as control groups. Cell viability were measured
as average of replicates (n = 3) with standard deviation (%); (C) The normal cell line L-02 was also
treated with NYG in a dose and time dependent manner. NYG exerted no cytotoxicity on HepG2 and
HCC97L or L-02 cells; (D) The relative mRNA expression of VEGF in MHCC97L cells determined by
qPCR. The VEGF mRNA was measured as fold change ˘ SD; (E) Amount of VEGF secretary protein of
MHCC97L cells in both normoxia and hypoxia conditions. The VEGF concentration was measured as
average ˘ SD (ng/nL). MHCC97L showed no significant changes in mRNA and protein concentration
of VEGF after NYG treatment.
2.4. NYG Reduced Migration and Tube Formation of HUVECs
Angiogenesis is the formation of new blood vessels with the purpose of supplying nutrients and
oxygen for tumor cell growth. The blood vasculature is mainly supported by the inter-connected
endothelial cells with the properties of invasion from basement membrane, migration, proliferation
and sprouts-formation [19]. Therefore, we further examined whether the in vivo tumor suppression
by NYG is attributed by reduced initiation of neovascularization by endothelial cells. Briefly, we
exposed the human umbilical vein endothelial cells (HUVEC) to VEGF, the angiogenesis-favoring
factor, alone or in combination with NYG and the behaviors of HUVEC were further investigated.
Similar to the results obtained from human cancer cells, we observed minimal cytotoxicity against
HUVEC induced by NYG up to concentration of 500 µg/mL. The 50% inhibitory concentration (IC50)
of NYG on HUVEC is approximately 2 mg/mL and 4 mg/mL with incubation time of 24 and 48 h,
respectively (Figure 4A). We then examine whether NYG reduces motility of HUVEC. Using matrigel
invasion chamber assay, we observed reduced percentage of migrated HUVEC from the apical side to
basal side of the chamber in the presence of NYG at non-toxic doses (Figure 4B). The motility blockade
of endothelial cells towards chemoattractant VEGF by NYG indicated that functions of endothelial
cells may be interrupted in the presence of NYG. Observation from tube formation assay supported the
hypothesis, as the formation of capillary-like tubular structure by HUVEC was completely attenuated
by NYG treatment (Figure 4C). The inhibitory effects of NYG at 100 µg/mL on HUVEC motility
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and tube formation are comparable to 30 µM of suramin, the angiogenesis inhibitor. Altogether, our
results indicated that NYG targeting on endothelial cells in suppressing the vasculature formation in
tumor stroma.Int. J. Mol. Sci. 2016, 17, 1277 7 of 13 
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that p-ERK was highly expressed on CD31 stained vasculature in xenografted tumor and intervention
of NYG suppressed the expression of p-ERK (Figure 5B). However, future study in observing the
changes of pERK in the relationship of variety time points and doses as well as any possibility of
affecting ERK downstream or upstream targets is definitely needed to confirm the role of ERK upon
NYG intervention. Overall, our results indicated that inhibition of ERK may be associated with
NYG-regulated inhibitory functions of endothelial cells.Int. J. Mol. Sci. 2016, 17, 1277 8 of 13 
 
 
Figure 5. Inhibition of tumor neovascularization by NYG may be related to ERK suppression in 
endothelial cells. (A) HUVECs were treated with VEGF alone or in combination with NYG. The 
lysates were immune-blotted against anti-pERK and GAPDH. The protein levels of pErk1 and pErk2 
were normalized with GAPDH and quantified, as shown in the right panel. NYG intervention 
downregulated the expression of p-ERK; (B) Histological sections of excised HCC tumor staining with 
CD31 and pERK antibodies in control and NYG-treated mice (10 mg/kg) (400× magnification). NYG 
intervention significantly reduced CD31-stained microvessel density in xenograft mice. The 
expression of p-ERK was reduced on CD31 stained vasculature in NYG intervention group compared 
to control group of mice. * p < 0.05, *** p < 0.001. 
3. Discussion 
Neovascularization is an essential process, allowing the expansion of tumor cells from the 
primary site. The process also involves the proliferation and migration of endothelial cells within 
tumor stroma; and formation of microvasculature by endothelial cells further supply sufficient 
oxygen and nutrients for the rapid tumor expansion [5]. Neovascularization is critically involved in 
progression of metastatic cancers [22]. Secretion of vascular endothelial growth factors (VEGF) by 
tumor cells has been postulated as the determinant factor [23]; however, in our study, we found that 
NYG has minor effect on the oncogenic property of HCC cells in vitro, and did not affect the 
expression and secretion of VEGF on HCC cells. This observation excludes the possibility that NYG 
target on upstream regulation of tumor neovascularization. The binding of VEGF to its membrane 
receptors, VEGFR, activates multiple intracellular signal transductions and allows transcriptional 
activation of proliferation, motility and permeability related genes [24]. Previous studies showed that 
activation of ERK signaling is majorly contributed to the functional expansion [25] and migration of 
endothelial cells [26]. We observed that in cultured endothelial cell line HUVEC, NYG potently 
suppressed the VEGF-induced phosphorylation of ERK signaling, indicating that activation of ERK 
by VEGF was blocked upon NYG intervention and this action may be VEGF-dependent (Figure 6). 
Figure 5. I i iti f t r neo asc l i ti be related to ERK suppres ion in
endothelial cells. (A) HUVECs were tr ated with VEGF alone or in combination with NYG. The lysates
were immune-blotted against nti-pERK and GAPDH. The protein levels of pErk1 and pErk2 were
normalized with GAPDH and quantified, as shown in the right panel. NYG intervention dow regulated
the expression of p-ERK; (B) Histological sections of excised HCC tumor staining with CD31 and pERK
antibodies in control and NYG-treated mice (10 mg/kg) (400ˆ magnification). NYG intervention
significantly reduced CD31-stained microvessel density in xenograft mice. The expression of p-ERK
was reduced on CD31 stained vasculature in NYG intervention group compared to control group of
mice. * p < 0.05, *** p < 0.001.
3.
Neovascularization is an ess ntial process, allowing the expansion of tum r cells f om the pri ary
site. The process also involves the pr if ration and migration of endothelial cells wi in tumor stroma;
and f rmation of microvasculature by endothelial cells further supply sufficient oxygen and n tr ents
f r th rapi tumor expansion [5]. Neovascularization is critically involved in progression of metastatic
cance s [22]. Secretion of vascular endothelial growth factors (VEGF) by tumor cells has been postulated
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on HCC cells. This observation excludes the possibility that NYG target on upstream regulation of
tumor neovascularization. The binding f VEGF to its membrane receptors, VEGFR, activates multiple
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permeability related genes [24]. Previous studies showed that activation of ERK signaling is majorly
contributed to the functional expansion [25] and migration of end thelial cell [26]. We observed that in
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cultured endothelial cell line HUVEC, NYG potently suppressed the VEGF-induced phosphorylation
of ERK signaling, indicating that activation of ERK by VEGF was blocked upon NYG intervention and
this action may be VEGF-dependent (Figure 6).Int. J. Mol. Sci. 2016, 17, 1277 9 of 13 
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It is noted that many nature derived anti-cancer compounds have poor solubility, low stability
and bioavailability, which hinder the progression of the use of natural product for cancer therapy [27].
The excipients of NYG, β-cyclodextrin (B-CD), has been widely used by pharmaceutical industries as
complexing agents, which have been scientifically proven to improve the drug solubility, bioavailability,
stability and safety to human body [28]. However, some studies also claimed that B-CD may cause
in vitro and in vivo toxicities to cell lines and animals. Previous studies have suggested that the route
of administration may render the toxicity of B-CD [29]. Our study therefore has included another
group of experimental animals with the intervention of B-CD, which showed minimal toxicity to the
animals as observed from the absence of obvious body weight decrease in the mice group with i.p.
administration. The in vitro studies revealed that 1% (w/v) of B-CD on HaCaT keratinocytes resulted
in 52.23% cell death [30] and 5 mmol/L (approximately 5.675 mg/mL) led to 60% death on P388
cells [31], further postulated the cytotoxicity of B-CD at certain high concentrations. Consistent with
the previous studies, our results showed that B-CD concentration below 500 µg/mL exerted no toxicity
to HepG2 and MHCC97L liver cancer cells. Therefore, we expected the concentration of 0.1 mg/mL of
NYG with the content of approximately 0.095 mg/mL of B-CD is non-toxic to the cells.
It is frequently observed in clinical practice in which the patients are associated with severe
adverse side effects like nausea, vomiting, diarrhea and lack of appetite after chemotherapy. These
side effects could be attributed to the toxic reaction on normal cells incurred by chemotherapeutics
agents [32]. Therefore, it seems to be an evitable issue in the use of chemotherapeutic agents with
direct toxicity to cancer cells. Besides, due to the chemo-resistant characteristics of HCC, the dose of
chemotherapeutic agents used may be much higher resulting in greater risk of adverse reactions. In our
observation, though NYG did not exhibit any toxicity to HCC cells, the fraction also presented minimal
effect on normal hepatic cells, which may suggest the safety of NYG on patients. The observation of
animal body weight changes under treatment of NYG also further supports the safe use of NYG, as
there is no adverse reaction or body weight loss observed at certain dose of NYG.
As observed in our study, the reduced tumor expansion by NYG is not due to shrinkage of tumor
cell population, but related to the restricted motility of endothelial cells and vasculature formation
within tumor stroma. Failure of constructing vascular network by endothelial cells limited the
oxygen and nutrients supply to the tumor cells, resulting in tumor growth retardation in NYG-treated
mice. NYG intervention may not completely eradicate tumor cells; however, the rapid growth and
proliferation of solid tumor was retarded. The tumor cells may remain at lower proliferation rate and
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vulnerable state in which low dose of chemotherapeutic agents may be employed to gain desirable
therapeutic outcome with minimal side effects. With these concerns, we regarded NYG as potential
adjuvant therapy to HCC, by restricting tumor expansion via neovascularization inhibition, and
may be used as complementary treatment to other first line cancer therapeutic agents. Future study
focusing on efficacy of combination use of first line treatment with NYG and the possible herbal–drug
interaction should be conducted to validate the hypothesis.
4. Materials and Methods
4.1. Preparation of NYG (Red Pigment from Saw Palmetto)
Saw palmetto powder was extracted with hot 90% ethanol (v/v). After extraction, the residue was
separated from the supernatant by filtration. The supernatant was then concentrated by evaporation.
After that, an equivalent of water was added to the concentrated extract with stirring. The mixture
allows settling at room temperature in order to achieve efficient separation between oil (upper) and
water (lower) phases. The water layer was collected in a separating funnel and the wet crystalline
component was harvested by filtration. This followed by addition of an equivalent weight of
beta-cyclodextrin (B-CD) and 3 times volume of 90% ethanol (v/v) to the wet crystalline material
and mixed well. The homogenized paste was dried under reduced pressure. The dried fraction was
re-slurried with 90% ethanol (v/v), and the fats and other impurities were washed out. The washed
slurry was dried again, and the net weight of crystalline material calculated. The final concentration
was adjusted by B-CD (20 times trituration), which means 1 portion of natural pigment extract of Saw
Palmetto was mixed with 19 portion of B-CD evenly.
4.2. Cell Line and Cell Culture
Human hepatocellular carcinoma cell lines HepG2 was purchased from ATCC and MHCC97L
was gifted by Dr. Man Kwan, Department of Surgery, The University of Hong Kong. L-02 cell
line was purchased from Experimental Animal Center of Sun Yat-sen University, Guangzhou. Cell
lines were maintained in DMEM (Gibco, Carlsbad, CA, USA) supplemented with 10% FBS and 1%
penicillin/streptomycin. HUVEC cell line was purchased from ATCC and it was maintained in EGM-2
complete medium (Lonza, Basel, Switzerland) at 5% of CO2 incubator. The cell lines were passaged
whenever they reached 80% confluency.
4.3. Cell Viability Assay
The cell viability was determined using MTT assay according to the previous publication by
Mosmann [33]. The cells were treated with serial concentrations of NYG for 24, 48 and 72 h. At the end
of the incubation, 10 µL of MTT solution was added to each well and incubated for another 3 h. One
hundred microliters of DMSO was added to dissolve formazan crystal before absorbance measurement
at wavelength of 570 nm.
4.4. Migration and Tube Formation Assay
For migration assay, HUVECs were seeded on transwell insert 8 µm (Costar). The receiving
chamber was filled with serum free cell culture medium supplemented with 20 ng/mL VEGF with
or without NYG and Suramin. The cells were allowed to migrate at 37 ˝C for 4 h. After that, the
remaining cells at upper insert were removed by cotton swab and cells at lower chamber were fixed
and stained with crystal violet. The number of migrating cells was counted in five fields per well
under microscope. As for tube formation assay, HUVECs with or without treatment were seeded on
a 96-well plate that was pre-coated with Matrigel basement membrane matrix (BD). The cells were
incubated at 37 ˝C for 4 h before visualized under microscope.
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4.5. Quantitative Real-Time PCR
Total RNA was extracted from NYG-treated cells using RNA isoplus reagent (Takara, Tokyo,
Japan). Reverse transcription was performed using cDNA reverse transcription kit (Takara).
Quantitative real-time PCR was performed with SYBR premix Ex Taq (Takara) with Light Cycler
480 real time PCR system (Roche, Basel, Switzerland). The primer sequence is as followed: VEGF
5’-CCTCCGAAACCATGAACTTT-3’ (forward) and 5’-TTCTTTGGTCTGCATTCACATT-3’ (reverse).
4.6. Western Blotting
The NYG-treated cells were lysed with RIPA buffer and protein concentration was determined
using Bradford protein assay. Ten micrograms of protein samples were separated on 12%
SDS-acrylamide gel before transferring to polyvinylidenedifluoride membranes. Membranes were
blocked with 5% bovine serum albumin before incubated with primary antibodies to rabbit
anti-GADPH and anti-phosphorylated ERK. The membrane were then incubated with horseradish
peroxidase-conjugated rabbit antibody and visualized under chemiluminescence system (Biorad,
CA, USA).
4.7. Immunohistochemistry
Tumors were fixed in 30% sucrose, freezed under ´20 ˝C in OCT and sectioned at thickness
of 8 µm. The sections were blocked by 10% goat serum and incubated with anti-mouse CD31
and p-ERK overnight. The multi vessel density of each section was evaluated through staining
with FITC conjugated antibody for 2 h and counterstained with DAPI before visualized under
fluorescent microscope.
4.8. ELISA Assay on VEGF Secretion
The VEGF secretion was measured using human VEGF ELISA kit (ExCell Biology) according to
the manufacturer’s protocol. The cell supernatant was seeded onto the plate pre-coated with anti-VEGF
monoclonal antibody. After that, the wells were incubated with HRP-conjugated streptavidin for
30 min before TMB substrate solution was added. Lastly, stop solution was added to terminate the
enzyme/substrate reaction and absorbance was determined at 450 nm.
4.9. Animal Studies
4.9.1. Subcutaneous Xenograft Model
MHCC97L cells (1 ˆ 106) in PBS were subcutaneously injected onto the right flank of
BALB/cAnN-nu athymic mice nude mice. After one week, serial doses of NYG and doxorubicin (n = 5)
treatment were initiated via intraperitoneal administration three times every week for four weeks.
Control group was administrated with the same volume of PBS. The weight and tumor size of each
mice were closely monitored. After the mice were sacrificed, the tumors were removed and measured.
The animal procedures were approved by the Committee on the Use of Live Animal in Teaching and
Research (CULATR) in The University of Hong Kong.
4.9.2. Orthotopic Implantation Model
The animal model establishment protocol has been described in our previous study [34]. In brief,
1 ˆ 106 luciferase-tagged MHCC97L cells in PBS was subcutaneously injected onto the right flank of
Balb/C nude mouse. The subcutaneous tumor was removed when it reached approximately 1 cm and
it was cut into 1 mm3 in pieces before implanted into the left lobe of another mouse liver. After one
week of laparotomy, the mice were subjected to luciferase imaging analysis for examination of any
tumor growth. The mice presenting signal of luciferase (n = 5) were randomized into control saline
group and NYG intervention group via intraperitoneal injection (10 mg/kg every 2 days). The weight
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and tumor growth of each mice were closely monitored every week. By the end of experiment, the
mice were sacrificed and liver tumors were removed. The animal procedures with reference number
of 3398-14 were approved on August, 2014 by the Committee on the Use of Live Animal in Teaching
and Research (CULATR), The University of Hong Kong.
4.10. Statistical Analysis
All data were statistically analyzed by unpaired Student’s t test. It was considered as significant
when p-value < 0.05.
5. Conclusion
In conclusion, we demonstrated the anti-tumor effect of NYG, the aqueous fraction of Saw
Palmetto Extract, on human hepatocellular carcinoma. NYG exhibited potent inhibitory effect of HCC
growth in both xenograft and orthotopic tumor models through suppression of neovascularization
in tumor stroma. NYG did not exert toxicity to HCC cells, nor could it reduce VEGF expression in
HCC cells. Instead, NYG suppressed the migration and sprout formation of endothelial cells in tumor
stroma, which might be the major contribution to its anti-tumor effect. This is associated with the
inactivation of ERK signaling on NYG-treated endothelial cells. Our study shed light on the novel use
of the aqueous fraction of Saw Palmetto as potential adjuvant therapy of HCC.
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